Page 216 - Pagetit
P. 216

6. CONCURRENT DISORDERS



                     Desai NG et al. (1984) Treatment of negative schizophrenia with d-amphetamine.
                     American Journal of Psychiatry, 141:723–724.
                     Di Chiara G et al. (1999) Drug addiction as a disorder of associative learning: role
                     of nucleus accumbens shell/extended amygdala dopamine. Annals of the New
                     York Acadamy of Sciences, 877:461–485.
                     Diwan A et al. (1998) Differential prevalence of cigarette smoking in patients with
                     schizophrenic vs mood disorders. Schizophrenia Research, 33:113–118.
                     Dixon L (1999) Dual diagnosis of substance abuse in schizophrenia: prevalence
                     and impact outcomes. Schizophrenia Research, 35 Suppl: S93–S100.
                     Dixon L et al. (1990) Acute effects of drug abuse in schizophrenic patients: clinical
                     observations and patients’ self-reports. Schizophrenia Bulletin, 16:69–79.
                     Dixon L et al. (1991) Drug abuse in schizophrenic patients: clinical correlates
                     and reasons for use. American Journal of Psychiatry, 148:224–230.
                     Duncan GE, Sheitman BB, Lieberman JA (1999) An integrated view of
                     pathophysiological models of schizophrenia. Brain Research Reviews, 29:250–264.
                     Edwards G (1990) Withdrawal symptoms and alcohol dependence: fruitful
                     mysteries. British Journal of Addiction, 85:447–461.

                     Ellenbogen MA et al. (1996) Mood response to acute tryptophan depletion in
                     healthy volunteers: sex differences and temporal stability. Neuropsychophar-
                     macology, 15:465–474.
                     Ellenbroek BA, Cools AR (2000) Animal models for the negative symptoms of
                     schizophrenia. Behavioural Pharmacology, 11:223–233.
                     Escamilla MA et al. (2002) Comorbidity of bipolar disorder and substance abuse
                     in Costa Rica: pedigree- and population-based studies. Journal of Affective
                     Disorders, 71:71-83.
                     Fatemi SH, Earle JA, McMenomy T (2000) Reduction in Reelin immunoreactivity
                     in hippocampus of subjects with schizophrenia, bipolar disorder and major
                     depression. Molecular Psychiatry, 5:654–663.
                     Feighner JP et al. (1984) A double-blind study of bupropion and placebo in
                     depression. American Journal of Psychiatry, 141:525–529.
                     Ferry LH, Burchette RJ (1994) Evaluation of buproprion versus placebo for
                     treatment of nicotine dependence. In: American Psychiatric Association New
                     Research, Washington, DC, American Psychiatric Press:199–200.

                     Finch DM (1996) Neurophysiology of converging synaptic inputs from the rat
                     prefrontal cortex, amygdala, midline thalamus, and hippocampal formation onto
                     single neurons of the caudate/putamen and nucleus accumbens. Hippocampus,
                     6:495–512.
                     Freedman R et al. (1997) Linkage of a neurophysiological deficit in schizophrenia
                     to a chromosome 15 locus. Proceedings of the National Academy of Sciences of
                     the United States of America, 94:587–592.
                     Frye MA et al. (2003) Gender differences in prevalence, risk, and clinical correlates
                     of alcoholism comorbidity in bipolar disorder. American Journal of Psychiatry,
                     160:883-889.


                                                     195




          Chapter_6                195                             19.1.2004, 11:49
   211   212   213   214   215   216   217   218   219   220   221